baber/WOPTO huggingface dataset:
Patent JP-2000509048-A (JP)
Title: 殺菌剤混合物
IPC: A01N37/52
Filed: 1997-04-03
Abstract: (57)【要約】
ａ 1 ）式Ｉ
 で表され、式中Ｘが酸素またはアミノ（ＮＨ）を、ＹがＣＨまたはＮを、Ｚが酸素、硫黄、アミノ（ＮＨ）またはＣ 1 −Ｃ 4 アルキルアミノ（Ｎ−Ｃ 1 −Ｃ 4 アルキル）を、Ｒ’がCＣ 1 −Ｃ 6 アルキル、Ｃ 1 −Ｃ 6 ハロアルキル、Ｃ 3 −Ｃ 6 アルケニル、Ｃ 2 −Ｃ 6 ハロアルケニル、Ｃ 3 −Ｃ 6 アルキニル、Ｃ 3 −Ｃ 6 ハロアルキニル、Ｃ 3 −Ｃ 6 シクロアルキルメチル、または部分的または完全にハロゲン化されてもよく、および／または１〜３個の以下の基、すなわちシアノ、Ｃ 1 −Ｃ 4 アルキル、Ｃ 1 −Ｃ 4 ハロアルキル、Ｃ 1 −Ｃ 4 アルコキシ、Ｃ 1 −Ｃ 4 ハロアルコキシ、Ｃ 1 −Ｃ 4 アルキルチオを有してもよいベンジルを意味するオキシムエーテル、から選択される少なくとも１種類の化合物ａ 2 ）式ＩＩ
 で表され、式中ＴがＣＨまたはＮを、ｎが０、１または２を、Ｒがハロゲン、Ｃ 1 −Ｃ 4 アルキル、またはＣ 1 −Ｃ 4 ハロアルキルを意味し、ｎが２の場合はＲが互いに異なってもよいカルバマート、およびｂ）化合物ＩＩＩおよびＩＶ
 から選択されるフタルイミド誘導体を、相乗活性量で含むことを特徴とする殺菌剤混合物。
Patent JP-2001524927-A (JP)
Title: ５，６，７，８―テトラヒドロピリド［２，３―ｄ］ピリミジン類
IPC: A61K31/519
Filed: 1996-09-17
Abstract: (57)【要約】
グルタミン酸誘導体であり、そのアミノ基が2-アミノ-5,6,7,8-テトラヒドロピリド[2,3-d]ピリミジン-6-イルアルキル-Z-カルボニル基で置換され、Ｚは二価で５メンバーの窒素含有複素環式環体系であり、オプションで硫黄または窒素原子を第２複素環メンバーとして含んでおり、抗腫瘍剤（抗新生物増殖阻害剤）として利用できる。典型的な実施例として、Ｎ-{3-[2-(2-アミノ-4-ヒドロキシ-5,6,7,8-テトラヒドロピリド[2.3-d]ピリミジン-6-イル)エチル]-ピラゾール-5-イルカルボニル}-L-グルタミン酸が例示できる。
Patent JP-2000513245-A (JP)
Title: 解剖学的に中立な人工関節
IPC: A61F2/42
Filed: 1997-04-25
Abstract: (57)【要約】
自然な角度の曲げ本体に固定されたステムと、正の曲げおよび伸長停止部と、前記ステムと前記本体の間の交差部分に圧力解放半径と、を備えた人工関節が示される。
Patent JP-2001523227-A (JP)
Title: 制御された溶解性の架橋タンパク質結晶
IPC: C12N11/00
Filed: 1998-04-10
Abstract: (57)【要約】
本発明は、結晶の環境の変化に際して、不溶性かつ安定な形態から可溶性かつ活性な形態へ変化する能力によって特徴づけられる架橋タンパク質結晶に関し、上記変化は、温度変化、pH変化、化学組成の変化、濃縮から希釈形態への変化、溶液の酸化還元電位の変化、入射放射線の変化、遷移金属濃度の変化、フッ化物濃度の変化、フリーラジカル濃度の変化、金属キレート剤濃度の変化、結晶に作用する剪断力の変化、およびこれらの組み合わせからなる群から選択される。本発明の１つの実施態様によれば、このような架橋タンパク質結晶は、そのタンパク質活性を制御された速度で放出可能である。本発明はまた、このような架橋タンパク質結晶を産生するための方法、タンパク質送達のためにそれらを使用する方法、および洗浄剤（界面活性剤を含む）、薬学的組成物、ワクチン、パーソナルケア組成物（化粧品を含む）、獣医学用組成物、食品、飼料、診断薬、および汚染除去のための処方物においてそれらを使用する方法を提供する。
Patent JP-2001523974-A (JP)
Title: 黄色種皮を有する改良ナタネの作成
IPC: A01H5/10
Filed: 1998-05-06
Abstract: (57)【要約】
黄色種皮を有するナタネを生成する植物中のナタネが与えられる。当該黄色種皮は単一遺伝子座の突然変異によって制御される。当該ナタネから得られた植物は、選り抜きのキャノーラ系統にその特性を移すのに有用である。
Patent JP-2001524181-A (JP)
IPC: F02B3/06
Filed: 1998-05-08
Abstract: An apparatus for producing a highly combustible fuel comprising a reactor chamber maintained under negative pressure, a nozzle for spraying an atomized fuel under pressure into the reactor chamber forming atomized droplets, a nozzle for introducing air into the reactor chamber to mix in a reactor zone with the atomized fuel for supplying a high voltage electrical potential differential, including at least one electrode located in the reaction zone, for providing an electrical charge to the atomized droplets, and means for passing the resulting atomized fuel and air to the manifold of an internal combustion engine.
Patent JP-2001525146-A (JP)
Title: 複合アンテナの検出と選択を行うシステム及びその方法
IPC: H04B7/08
Filed: 1998-05-13
Abstract: (57)【要約】
複合アンテナからの衛星通信信号を選択し、結合するシステムとその方法。システムは少なくとも、それぞれが分離したアンテナ（２０２Ａ−２０２Ｎ）に接続される二つの信号パス（５５０Ａ，５５０Ｂ）と、信号プロセッサ（２１６）により処理される二つのパスからの信号を合成する合成器（４３０）とを有している。少なくとも二つのパス（５５０Ａ，５５０Ｂ）の中の一つは、信号遅延ユニット（４１０Ａ−４１０Ｂ）を有している。信号プロセッサ（２１６）は、複数アンテナ（２０２Ａ−２０２Ｎ）の中の一つのソースから受信した信号を、他のアンテナのソースから受信した信号から、信号遅延ユニット（４１０Ａ，４１０Ｂ）により供給された信号遅延に基づいて識別する。信号プロセッサ（２１６）は、信号パス（５５０）に沿って受信した信号の品質を決定し、信号品質に関するデータを制御プロセッサ（２２０）へ供給するもので、この制御プロセッサは、最高信号品質を有する信号パス（５５０）を信号プロセッサ（２１６）へ接続するアッテネータを制御するものである。
Patent MD-20030270-A (MD)
Inventor: KOVALENKO NIKOLAE
IPC: G02B6/44
Filed: 2003-11-14
Abstract: Inventia se refera la tehnica de fibre optice, in special la dispozitivele de iluminare pentru cabluri si ecrane. Iluminatorul pentru cabluri de fibre optice contine un dispozitiv de schimbare a culorilor, executat in forma de cablu de fibre optice cu intrarile unite la sursele de lumina colorata, care trebuie sa fie amestecate, iar cu iesirile unite intre ele. Schimbarea culorii luminii la iesirea cablului este obtinuta prin schimbarea intensitatii luminii unei surse aparte si prin conectarea sau deconectarea unor surse aparte de lumina. ŕ
Patent NZ-192819-A (NZ)
Title: Article carrying crate from fold up sheet
Inventor: STOUT J T
IPC: B65D71/00
Filed: 1980-02-07
Abstract: An article carrier for the packaging of multiple articles comprises a bottom (2), side walls (1,11) joined to the side edges of the bottom, end wall panels (7,9,12,13) joined to the end edges of the side walls, a pair of medial partition or riser panels (16,17) joined respectively to the end wall panels at one end of the carrier and extending inwardly therefrom, a pair of riser panels (26,27) foldably joined respectively to the end wall panels at the other end of the carrier and extending inwardly therefrom, a multiple ply handle (49,50,51,52) secured to the medial partition panels and the riser panels, and a locking tab (67) foldably joined to one of the handle panels and disposed intermediate the riser panels.
Patent NZ-194557-A (NZ)
Title: Substituted pyranone derivatives;dihydroxy acids therefrom;pharmaceutical compositions
Inventor: WILLARD A K
IPC: C07C59/48
Filed: 1980-08-04
Abstract: 6-Phenyl, phenalkyl- and phenylethenyl-4-hydroxytetrahydropyran-2-ones in the 4- R trans stereoisomeric forms having the structure <CHEM>  wherein  A is H or methyl;  E is a direct bond, -CH2-, -CH2-CH2-, -CH2-CH2-CH2- or -CH=CH-; and  R1, R2 and R3 have several meanings, and the corresponding dihydroxy acids in which the lactone ring is hydrolytically opened, and the pharmaceutically acceptable salts of said dihydroxy acids, and the lower alkyl and the phenyl, dimethylamino or acetylamino-substituted  lower alkyl esters of said dihydroxy acids; and processes for preparing  them. These compounds are potent inhibitors of cholesterol synthesis by the enzyme hydroxymethyl glutaryl coenzyme A reductase.
Patent NZ-201006-A (NZ)
Title: N-oxacyclyl-alkylpiperidine derivatives and pharmaceutical compositions
Inventor: HENNING R
IPC: A61K31/443
Filed: 1982-06-18
Abstract: Neuroleptically active compounds of the formula   <IMAGE>   wherein R6 and R10 are -H or CH3; R7 and R8 are independently -H, -F, -Cl, or -CH3; and R9 is -F, -Cl, -CH3, or -OCH3.
Patent NZ-204527-A (NZ)
Title: Dielectric fluid containing tetrachlorodifluoroethane and perchloroethylene
Inventor: LLOYD H
IPC: H01F27/10
Filed: 1983-06-10
Abstract: Dielectric, cooling or arc-extinguishing fluids comprise a mixture of tetrachlorodifluoroethane and perchloroethylene, optionally with incorporation of a third component which is preferably trichlorotrifluoroethane. Transformer and circuit-interrupter apparatus containing such dielectric fluids are also described.
Patent NZ-207677-A (NZ)
Title: Opaque dental porcelain containing urethane polymer
Inventor: MARTIN B
IPC: A61K6/884
Filed: 1984-11-28
Abstract: An opaque porcelain paste comprising an opaque porcelain powder mixed with an aqueous colloidal dispersion of a urethane polymer. The paste can be applied as the first layer to a dental coping, and does not need to be fired prior to the addition of the body porcelain layers.
Patent NZ-212387-A (NZ)
Title: N-substituted-4-substituted-trans decahydroquinoline derivatives, and pharmaceutical compositions containing such
Inventor: PROST M
IPC: C07D215/233
Filed: 1985-06-12
Abstract: The invention relates to novel decahydroquinolinol derivatives represented by the general formula:   <IMAGE>   and pharmaceutically acceptable acid addition salts thereof, in which X represents oxygen or sulphur, R represents an alkyl radical having from 1 to 3 carbon atoms, R1 represents fluorine, chlorine, bromine or methoxy, R2 represents hydrogen or methoxy or R1 and R2, when they are taken together, represent a 2,3-methylenedioxy or 3,4-methylenedioxy radical. The compounds of the invention are inhibitors of calcium translocation at the level of the cell membrane and are useful more particularly in the treatment of pathological syndromes of the cardiovascular system such as, for instance, angina pectoris.
Patent NZ-214535-A (NZ)
Title: Nuclease treatment of broth culture
Inventor: DROZD J W
IPC: C12P19/06
Filed: 1985-12-12
Abstract: Method of improving the filterability of a microbial broth containing microbial cell matter resulting from the breaking down of cells, which comprises contacting that broth with one or more enzymes having nuclease activity; use of the method for improving the flow of a microbial polysaccharide containing fluid displacement solution which is applied in enhanced oil recovery.
Patent NZ-232322-A (NZ)
Title: Disintegratable tablet containing gemfibrozil in two granulation forms to provide both immediate and enteric release
Inventor: GHEBRE-SELLASSIE ISAAC
IPC: A61P3/06
Filed: 1990-01-31
Abstract: A disintegratable gemfibrozil tablet providing both immediate and enteric release is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder and a second granulation formed from the first granulation but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
Patent NZ-235716-A (NZ)
Title: Pharmaceutical compositions containing 4-benzyl- or 4-(1-phenethyl) imidazole derivatives
Inventor: KALSO EIJA
IPC: C07D233/58
Filed: 1990-10-16
Abstract: This invention relates to local epidural or intraspinal use of compounds of the formula: <CHEM> where X is H or CH3 and R1 and R2, which can be the same or different, are each H or CH3 and their stereoisomers and their non-toxic, pharmaceutically acceptable salts. Especially useful are the compounds known under the generic names medetomidine ((+/-)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole), dexmedetomidine (+)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole and detomidine 4-(2,3-dimethylbenzyl)-1H-imidazole.
Patent NZ-236252-A (NZ)
Title: 6-substituted benzothiazolinone derivatives, preparation and pharmaceutical compositions thereof
Inventor: LESIEUR ISABELLE
IPC: A61K31/428
Filed: 1990-11-28
Abstract: Compounds of general formula (I):   <IMAGE> (I)  in which: R1 represents a hydrogen atom or a lower alkyl group, and R2 represents a substituted or unsubstituted alkyl, a phenyl or a substituted or unsubstituted heteroaryl, their enantiomers, diastereoisomers and epimers and their addition salts with a pharmaceutically acceptable base when R1 represents a hydrogen atom or when R2 comprises a carboxylic acid group. Medicinal products.
Patent NZ-236515-A (NZ)
Title: Use of quaternary ammonium ionene polymers for sterilising contact lens, and composition therefor
Inventor: DZIABO ANTHONY J
IPC: A61L12/14
Filed: 1990-12-18
Abstract: Ophthalmic compositions, such as those used to care for contact lenses, methods of preserving such compositions, and methods for disinfecting contact lenses using such compositions are disclosed. The compositions may comprise an ophthalmically acceptable, liquid aqueous medium and, included therein, an effective preserving or disinfecting amount of certain oxygen-containing ionene polymers.
Patent NZ-278643-A (NZ)
Title: Layered tablet: active agents and gelling agents in separate layers of the tablet
Inventor: BASTIN RICHARD JAMES
IPC: A61K9/34
Filed: 1995-01-24
Abstract: This invention relates to an abuse resistant tablet containing two or more layers having one or more drugs and one or more gelling agents and its preparation. The drug(s) and gelling agent(s) are in separate layers of the tablet. The multilayer tablet is particularly suitable for the administration of drugs prone to abuse by unauthorized parenteral administration such as analgesics, hypnotics, and anxiolytics.
Patent NZ-279396-A (NZ)
Title: Octahydro-6-hetring[2,1-a][2]benzazepine disulphide derivatives
Inventor: FLYNN GARY ALAN
IPC: C07D471/04
Filed: 1995-01-09
Abstract: The present invention relates to certain novel indane-2-mercaptoacetylamide disulfide derivatives of the formula    <IMAGE>  Formula (I)  useful as inhibitors of enkephalinase.
Patent NZ-306517-A (NZ)
Title: Closure device for containers comprising a circular-cross section of a moulded foamed closed-cell polymer having a uniform density of at least 0.03 g/cc.
Inventor: TAYLOR DAVID GRAHAM
IPC: B41M1/40
Filed: 1996-05-03
Abstract: A closure device for a container such as a wine bottle comprising a body (1) of circular cross section, preferably cylindrical, which is adapted to fit in an opening in the container to seal said container said body consisting essentially of a moulded foamed closed-cell polymer of copolymer, preferably expanded polystyrene, having a substantially uniform density of at least 0.03 g/cc. The closure device may be partially or wholly coated with a sealing material (5), waxed, coloured and/or surface-treated to render it even closer in appearance to cork, and printed on.
Patent NZ-331192-A (NZ)
Title: Adaptor to convert standard gearbox to sequential gearbox using piston(s) and clutch(es)
Inventor: GOATLEY ERNEST PAUL
IPC: B60K20/00
Filed: 1999-07-26
Abstract: ub 4 is splined to rotate with shaft 3.  Gears 5, 6 are free to rotate on shaft 3 but are fixed axially.  Annular pistons 7, 8 are movable axially by fluid pressure via ports 15, 15a, 16,  16a.  Outward movement of pistons 7, 8 squeezes plates 25, 26 which are alternately splined to shaft 3 and hub 4.  Sequential control via microswitches  is also disclosed.
Patent NZ-334026-A (NZ)
Title: Automatically muting TV commercials, broadcast monitored by central server, and commercial indications sent over Internet
Inventor: WAUGH IAIN WALLACE
IPC: H04N5/44
Filed: 1999-03-09
Abstract: A system for muting television commercials includes a data service provider, which communicates with a processor (14) and an IR transceiver (18) in a viewer's home.  The IR transceiver  (18) detects the channel that the viewer is watching by monitoring the television remote control (8).  When the processor (14) detects that a commercial is starting on the channel being viewed, a signal is sent to the IR transceiver (18), which then sends a mute signal to the television.  At  the end of the commercial segment the processor (14) signals the IR transceiver (18) to restore sound to the television.
Patent NZ-334482-A (NZ)
Title: Dietary foodstuff comprising zinc (20-28mg and above/400kcal) and linoleic acid (4-6g and above /400kcal)
Inventor: MARSH KATRINA ANNE
IPC: A23K1/16
Filed: 1998-06-12
Abstract: A diet or foodstuff comprising: a) zinc chosen from zinc sulphate, zinc oxide, or organic zinc at a concentration of above 28mg/400kcal and linoleic acid selected from safflower oil, sunflower oil, soyabean oil at a concentration of 4g/400kcal; or b) zinc at a concentration of 20mg/400kcal or above and linoleic acid at a concentration of 6g/400kcal or above The above foodstuff is used for dogs, cats, horses or humans.
Patent NZ-335525-A (NZ)
Title: Pouch for cooling and storing vials of, e.g. insulin, comprising a hinged double-skinned textile web member
Inventor: WOLSEY HENRY GARNET
IPC: A61J3/00
Filed: 1997-10-23
Abstract: A portable flexible cooling pouch for cooling and storing vials containing medication comprises opposed web members 2, 3 made of a water permeable material and being connected at the edges thereof.  The web members include a first double-skinned web portion interconnected via a hinge portion 8 at an edge thereof to a second double-skinned web portion.  At least one of the web members comprises a plurality of compartments 4a, 4b, 4c which contain a water-absorbent granular material 5.
Patent NZ-336009-A (NZ)
Title: Soluble CTLA4 mutant molecules which bind to CD86 antigen
Inventor: PEACH ROBERT J
IPC: C12N5/0783
Filed: 1998-01-29
Abstract: A soluble CTLA4 mutant molecule which binds CD86 has an amino acid sequence shown in specification, wherein the amino acid at position 29 designated Xaa is alanine or tyrosine and the amino acid at position 106 designated Yaa is glutamic acid, asparagine, aspartic acid, glutamine, isoleucine, leucine, or threonine. A soluble mutant CTLA4Ig fusion protein reactive with the CD86 antigen has a first amino acid sequence consisting of the extracellular domain of CTLA4 mutant as shown in specification and a second amino acid sequence consisting of the hinge, CH2 and CH3 regions of human immunoglobulin Cyl. An isolated nucleic acid molecule and its equivalent cDNA encoding the amino acid sequence corresponding to the soluble mutant CTLA4 or soluble mutant CTLA4Ig fusion protein as defined above are disclosed. Also disclosed are a plasmid comprising the cDNA as defined above and a host vector system comprising the plasmid. The soluble CTLA4 mutant molecule as defined above is useful for regulating functional CTLA4 positive T-cell interactions with CD80 and CD86 positive cells such as for treating immune system diseases mediated by T cell interactions with CD80 and CD86 positive cells. The soluble CTLA4 mutant molecule as defined above and a ligand reactive with IL-4 are used in the manufacture of a medicament for inhibiting graft versus host disease in a subject.
Patent NZ-337379-A (NZ)
Title: Use of isolated tyrosinase derived peptides in treating cellular abnormality
Inventor: LETHE BERNARD
IPC: A61K39/385
Filed: 1999-08-20
Abstract: The use of an agent which provokes a cytolytic response to cells presenting complexes of an HLA-B44 molecule and a peptide of the formula Xaa Glu Ile Trp Arg Asp Ile Asp Phe (Sequence ID 12); wherein Xaa is any amino acid but SER for treating a subject with cellular abnormality; characterised by the expression of complexes of HLA-B44 and the peptide.
Patent NZ-500736-A (NZ)
Title: Method for recovery of recombinantly produced polypeptides involving the cleavage of fusion proteins
Inventor: MOLONEY MAURICE
IPC: A23L1/305
Filed: 1998-04-23
Abstract: A method for the preparation of a recombinant polypeptide comprising a) Introducing into a host cell an expression vector comprising: 1) A nucleic acid sequence capable of regulating transcription into a host cell, operatively linked to 2) A chimeric nucleic acid sequence encoding a fusion protein, the chimeric nucleic acid sequence comprising (a) A nucleic acid sequence encoding a pro-peptide derived from an autocatalytically maturing zymogen, linked in reading frame to (b) a nucleic acid sequence heterologous to the pro-peptide and encoding the recombinant polypeptide, wherein the heterologous nucleic acid sequence is located immediately downstream of the nucleic acid sequence encoding the pro-peptide; operatively linked to 3) A nucleic acid sequence encoding a termination region functional in said host cell b) Growing the host cell to produce said fusion protein; and c) Altering the environment of the fusion protein so that the pro-peptide is cleaved from the fusion protein to release the recombinant polypeptide, but excluding a human host cell in situ. Altering the environment can take place under in vitro or in vivo conditions. The fusion protein produced can be used to prepare pharmaceutical compositions or food compositions. The medicaments prepared are for delivering a therapeutic or nutritional protein to a human or animal.
Patent NZ-502987-A (NZ)
Title: Ride-on mower having bag-full indicator
Inventor: MIXON LARAMIE W
IPC: A01D34/63
Filed: 1998-07-30
Abstract: A lawn mower comprising a frame, an engine mounted on the frame, a cutting mechanism driven by the engine constructed and arranged to cut grass and to generate grass clippings, a bag (26) for collecting said grass clippings, and a bag-full indicating assembly. The bag-full indicating assembly includes an indicator (30) that indicates to a mower operator that the bag is substantially full in response to a bag-full signal, and a switch (28) which can be activated to generate the bag-full signal. The switch comprises a grass-contacting member extending into the bag. The grass-contacting member is movable from a non-activated state to an activated state by being displaced by grass clipping build-up within the bag. The switch thereby enables the bag-full signal for the indicator so that the indicator indicates to the mower operator that the bag is substantially full.
Patent NZ-504840-A (NZ)
Title: G-CSF hybrid compositions suitable for treating disorders requiring the recruitment of neutrophils
Inventor: OSSLUND TIMOTHY D
IPC: G06F19/00
Filed: 2000-05-30
Abstract: A G-CSF hybrid molecule comprised of a G-CSF analog moiety and a biologically active protein moiety characterised by: a) Having amino acids 2-175 of Sequence ID 2 optionally with an N-terminal methionyl residue; b) Having an overall three-dimensional conformation as set forth in Figure 4 comprising: i) An anti-parallel 4-alpha helical bundle with a left hand twist; ii) An overall dimension of 45å x 30å x 24å; and iii) A helix crossing angles ranging from -167.5o to -159.4o; and c) Having a biologically active protein attached to an amino acid selected from among amino acids 119-145 of the CD loop of Sequence ID No. 2. G-CSF hybrids are useful for selectively stimulating neutrophil production to compensate for hematopoietic deficits resulting from chemotherapy or radiation therapy.
Patent NZ-506810-A (NZ)
Title: A sterilizing method by substituting the dissolved oxygen in milk or the like with nitrogen gas, a product thereof and an apparatus for nitrogen gas substitution
Inventor: KAMIYA TETSU
IPC: B01F3/04
Filed: 2000-09-07
Abstract: A method for reducing the amount of oxygen from liquids including milk products and fruit juice beverages. The method involves dividing the mixture between two pipes, A and B, that lead into a tank with a substantially nitrogen gas atmosphere. The liquid in pipe A has nitrogen gas mixed or dispersed through it, via a device found at the end of the pipe, before it flows into the tank. The liquid in pipe B is sprayed on top of the liquid from pipe A as it flows into the tank. The mixture is held in the tank and then possibly homogenized or preheated before being sterilized and filled into containers.
Patent NZ-508509-A (NZ)
Title: Process for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethylbenzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
Inventor: DAMON DAVID BURNS
IPC: C07D215/20
Filed: 2000-11-29
Abstract: A process for preparing (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester comprises; a. combining vinyl-carbamic acid-R1, (wherein R1 is benzyl), (1-benzotriazol-1yl-propyl)-(4-trifluoromethyl-phenyl)-amine and 4-toluene-sulfonic acid monohydrate in toluene at a temperature of about 50°C to about 90°C to prepare cis-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid-R1-ester; b.    combining the product of (a) with pyridine and ethyl chloroformate in dichloromethane to prepare cis-4-R1-oxycarbonylamino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; c.     combining the product of (b) and ammonium formate in methanol with palladium/carbon to form a slurry and heating the resulting slurry at a temperature of about 35°C to about 60°C for about 30 minutes to about 3 hours to prepare 4-amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; d.    combining the product of (c) and (-)dibenzoyl-L-tartaric acid or (-)di-p-toluoyl-L-tartaric acid to form the (-)dibenzoyl-L-tartaric acid salt or (-)di-p-toluoyl-L-tartaric acid salt thereof; e.  combining the salt of (d), 1,2-dichloroethane and an aqueous base with 3,5-bis(trifluoromethyl)benzaldehyde, followed by the addition of sodium triacetoxyborohydride to form a product; f.  combining the product of (e) and 4-toluene sulfonic acid monohydrate to prepare (- )-(2R,4S)-4-(3,5-bis-trifluoromethyl-benzylamino )-2-ethyl-6trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, 4toluene-sulfonate; and g.  combining the product of (f), tosylate salt, sodium carbonate and methyl chloroformate in tetrahydrofuran at a temperature of about 20°C to about 25°C.